Dhatakyadi Varti-An Advance Therapy for Vulvovaginitis During Pregnancy

â??A CLINICAL STUDY ON UPAPLUTA YONIVYAPAD w.s.r. TO VULVOVAGINITIS DURING PREGNANCY & ITS MANAGEMENT WITH DHATAKYADI VARTIâ??

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/05/005747

Enrollment

Registered

2015-05-05

Start date

Unknown

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: TRIAL DRUG AND CLOTRIMAZOLE,CLINDAMYCIN VAGINAL SUPPOSITORIES: PATIENT WERE RANDOMLY DIVIDED IN TWO GROUPS.IN TRAIL GROUP DHATAKYADI VARTI(3G) WAS INSERTED LOCALLY IN VAGINA AT BED TI

Eligibility

Inclusion criteria

Inclusion criteria: 1.The pregnant women with different parity having signs and symptoms of vulvovaginitis. 2.Age 19 to 40years. 3.White discharge present during examination. 4.Inflammation present in vulva and vagina. 5.Pathogens present in wet slide study and vaginal swab culture.

Exclusion criteria

Exclusion criteria: 1.Non pregnant Women. 2.Age below 19yrs or above 40 yrs 3.Hypersensitivity to drug and inability to conform the protocol. 4.Women with severe Physical illness, any systemic disease like D.M.,any organic Pathology, Hepatic, Cardiac, Renal disease and any acute Infection of any system, 5.Women suffering from disease like S.T.D.,H.I.V.etc.

Design outcomes

Primary

Measure	Time frame
PATIENT GOT SYMPTOMATIC RELIVE IN BOTH GROUPSTimepoint: AFTER 14 DAYS OF TREATMENT	—

Secondary

Measure	Time frame
TO PREVENT COMPLICATION LIKE PRE MATURE RUPTURE OF MEMBRANE AND PRE TERM LABORTimepoint: TO PREVENT COMPLICATION LIKE PRE MATURE RUPTURE OF MEMBRANE AND PRE TERM LABOR	—

Countries

India

Contacts

Public ContactDR SHILPA DONGA

MD (AYU)PHD

drshilpadonga@yahoo.com9825646796

Outcome results